NASDAQ:NAUT Nautilus Biotechnology Q3 2026 Earnings Report $1.44 +0.08 (+5.86%) As of 11:38 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nautilus Biotechnology EPS ResultsActual EPSN/AConsensus EPS -$0.14Beat/MissN/AOne Year Ago EPSN/ANautilus Biotechnology Revenue ResultsActual RevenueN/AExpected Revenue$0.21 millionBeat/MissN/AYoY Revenue GrowthN/ANautilus Biotechnology Announcement DetailsQuarterQ3 2026Date10/27/2026TimeBefore Market OpensConference Call DateTuesday, October 27, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Nautilus Biotechnology Earnings HeadlinesRoth Capital initiates coverage of Nautilus Biotechnology with buySeptember 29 at 12:37 AM | msn.comNautilus Biotechnology Analyst Price TargetsSeptember 10, 2026 | benzinga.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 30 at 1:00 AM | TradeSmith (Ad)Leerink Partners initiates coverage of Nautilus Biotechnology with outperformSeptember 10, 2026 | msn.comNautilus Biotechnology Reveals Tau Proteoform Insights In Nature Methods PublicationSeptember 4, 2026 | rttnews.comNature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau ProteoformsSeptember 4, 2026 | globenewswire.comSee More Nautilus Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nautilus Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nautilus Biotechnology and other key companies, straight to your email. Email Address About Nautilus BiotechnologyNautilus Biotechnology (NASDAQ:NAUT) is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods. The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine. Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington. The company was co-founded by Sujal Patel, who serves as chief executive officer, and Mark Oldham. Nautilus became a publicly traded company on the Nasdaq in 2021 through a business combination with Arya Sciences Acquisition Corp. III.View Nautilus Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
